Ortivus AB (publ) (ORTI-B.ST)
SEK 1.48
(-6.62%)
SEK 1.48
(-6.62%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.57 Million SEK | -14.17% |
| 2022 | 4.16 Million SEK | 104.02% |
| 2021 | 2.04 Million SEK | 1357.86% |
| 2020 | 140 Thousand SEK | -81.72% |
| 2019 | 766 Thousand SEK | 28.74% |
| 2018 | 595 Thousand SEK | -61.56% |
| 2017 | 1.54 Million SEK | -72.07% |
| 2016 | 5.54 Million SEK | -21.62% |
| 2015 | 7.07 Million SEK | 104.84% |
| 2014 | 3.45 Million SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | -100.0% |
| 2008 | 28.8 Million SEK | 123.69% |
| 2007 | 12.87 Million SEK | -38.25% |
| 2006 | 20.85 Million SEK | -31.44% |
| 2005 | 30.41 Million SEK | 0.0% |
| 2004 | - SEK | 0.0% |
| 2003 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.5 Million SEK | 0.0% |
| 2024 Q2 | 1.25 Million SEK | -16.67% |
| 2023 Q3 | 13.18 Million SEK | 169.05% |
| 2023 FY | 3.57 Million SEK | -14.17% |
| 2023 Q2 | 4.9 Million SEK | -19.07% |
| 2023 Q1 | 6.05 Million SEK | 45.46% |
| 2023 Q4 | 3.57 Million SEK | -72.9% |
| 2022 FY | 4.16 Million SEK | 104.02% |
| 2022 Q4 | 4.16 Million SEK | 138.08% |
| 2022 Q2 | 1.74 Million SEK | 0.0% |
| 2022 Q1 | 1.74 Million SEK | -14.31% |
| 2022 Q3 | 1.74 Million SEK | 0.0% |
| 2021 FY | 2.04 Million SEK | 1357.86% |
| 2021 Q2 | 1.71 Million SEK | 9.35% |
| 2021 Q4 | 2.04 Million SEK | 43.63% |
| 2021 Q3 | 1.42 Million SEK | -17.34% |
| 2021 Q1 | 1.57 Million SEK | 1022.86% |
| 2020 Q3 | 156 Thousand SEK | -63.72% |
| 2020 Q4 | 140 Thousand SEK | -10.26% |
| 2020 Q1 | 702 Thousand SEK | -8.36% |
| 2020 Q2 | 430 Thousand SEK | -38.75% |
| 2020 FY | 140 Thousand SEK | -81.72% |
| 2019 Q3 | 1.25 Million SEK | -1.02% |
| 2019 FY | 766 Thousand SEK | 28.74% |
| 2019 Q1 | 2.48 Million SEK | 316.81% |
| 2019 Q2 | 1.27 Million SEK | -48.79% |
| 2019 Q4 | 766 Thousand SEK | -39.06% |
| 2018 Q4 | 595 Thousand SEK | -37.63% |
| 2018 Q2 | 952 Thousand SEK | -20.0% |
| 2018 FY | 595 Thousand SEK | -61.56% |
| 2018 Q1 | 1.19 Million SEK | -23.13% |
| 2018 Q3 | 954 Thousand SEK | 0.21% |
| 2017 Q4 | 1.54 Million SEK | 0.0% |
| 2017 Q1 | 800 Thousand SEK | -85.56% |
| 2017 FY | 1.54 Million SEK | -72.07% |
| 2017 Q2 | 200 Thousand SEK | -75.0% |
| 2017 Q3 | - SEK | -100.0% |
| 2016 Q4 | 5.54 Million SEK | 23.16% |
| 2016 FY | 5.54 Million SEK | -21.62% |
| 2016 Q2 | 4.3 Million SEK | -20.37% |
| 2016 Q1 | 5.4 Million SEK | -23.63% |
| 2016 Q3 | 4.5 Million SEK | 4.65% |
| 2015 Q1 | 515 Thousand SEK | -85.08% |
| 2015 FY | 7.07 Million SEK | 104.84% |
| 2015 Q3 | 8.88 Million SEK | -11.8% |
| 2015 Q4 | 7.07 Million SEK | -20.41% |
| 2015 Q2 | 10.07 Million SEK | 1855.92% |
| 2014 Q4 | 3.45 Million SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 FY | 3.45 Million SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2009 FY | - SEK | -100.0% |
| 2008 FY | 28.8 Million SEK | 123.69% |
| 2007 FY | 12.87 Million SEK | -38.25% |
| 2006 FY | 20.85 Million SEK | -31.44% |
| 2005 FY | 30.41 Million SEK | 0.0% |
| 2004 FY | - SEK | 0.0% |
| 2003 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AddLife AB (publ) | 2.53 Billion SEK | 99.859% |
| Biotage AB (publ) | 150 Million SEK | 97.617% |
| Bonesupport Holding AB (publ) | 13.22 Million SEK | 72.969% |
| Doxa AB (publ) | 3.6 Million SEK | 0.722% |
| Elekta AB (publ) | 4.8 Billion SEK | 99.926% |
| iZafe Group AB (publ) | 279 Thousand SEK | -1181.004% |
| Ortivus AB (publ) | 3.57 Million SEK | 0.0% |
| Q-linea AB (publ) | 12.9 Million SEK | 72.305% |
| S2Medical AB (publ) | - SEK | -Infinity% |
| Synsam AB (publ) | 2.02 Billion SEK | 99.824% |